Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of acquired immune deficiency syndromes"
DOI: 10.1097/qai.0000000000002787
Abstract: BACKGROUND Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in… read more here.
Keywords: years dolutegravir; plus lamivudine; hiv; five years ... See more keywords